Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Capital Expenditures (2016 - 2025)

Iradimed (IRMD) has disclosed Capital Expenditures for 13 consecutive years, with $7.2 million as the latest value for Q4 2025.

  • Quarterly Capital Expenditures rose 2610.34% to $7.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.8 million through Dec 2025, up 856.28% year-over-year, with the annual reading at $7.8 million for FY2025, 856.28% up from the prior year.
  • Capital Expenditures for Q4 2025 was $7.2 million at Iradimed, up from -$5.8 million in the prior quarter.
  • The five-year high for Capital Expenditures was $7.2 million in Q4 2025, with the low at -$6.3 million in Q4 2023.
  • Average Capital Expenditures over 5 years is $511305.5, with a median of $183335.5 recorded in 2022.
  • Peak annual rise in Capital Expenditures hit 3307.03% in 2023, while the deepest fall reached 2556.83% in 2023.
  • Over 5 years, Capital Expenditures stood at $89200.0 in 2021, then surged by 189.39% to $258136.0 in 2022, then plummeted by 2556.83% to -$6.3 million in 2023, then skyrocketed by 104.21% to $266802.0 in 2024, then skyrocketed by 2610.34% to $7.2 million in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $7.2 million, -$5.8 million, and $2.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.